These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 16710314)
21. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009 [TBL] [Abstract][Full Text] [Related]
22. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465 [TBL] [Abstract][Full Text] [Related]
23. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294 [TBL] [Abstract][Full Text] [Related]
24. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects. Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362 [TBL] [Abstract][Full Text] [Related]
25. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418 [TBL] [Abstract][Full Text] [Related]
27. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399 [TBL] [Abstract][Full Text] [Related]
28. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549 [TBL] [Abstract][Full Text] [Related]
29. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890 [TBL] [Abstract][Full Text] [Related]
30. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930 [TBL] [Abstract][Full Text] [Related]
31. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448 [TBL] [Abstract][Full Text] [Related]
32. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Auclair AL; Galinier A; Besnard J; Newman-Tancredi A; Depoortère R Psychopharmacology (Berl); 2007 Jul; 193(1):45-54. PubMed ID: 17393144 [TBL] [Abstract][Full Text] [Related]
33. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244 [TBL] [Abstract][Full Text] [Related]
34. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787 [TBL] [Abstract][Full Text] [Related]
35. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085 [TBL] [Abstract][Full Text] [Related]
36. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537 [TBL] [Abstract][Full Text] [Related]
37. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105 [TBL] [Abstract][Full Text] [Related]
38. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Ichikawa J; Ishii H; Bonaccorso S; Fowler WL; O'Laughlin IA; Meltzer HY J Neurochem; 2001 Mar; 76(5):1521-31. PubMed ID: 11238736 [TBL] [Abstract][Full Text] [Related]
39. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Hagiwara H; Fujita Y; Ishima T; Kunitachi S; Shirayama Y; Iyo M; Hashimoto K Eur Neuropsychopharmacol; 2008 Jun; 18(6):448-54. PubMed ID: 18164909 [TBL] [Abstract][Full Text] [Related]
40. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Cosi C; Waget A; Rollet K; Tesori V; Newman-Tancredi A Brain Res; 2005 May; 1043(1-2):32-41. PubMed ID: 15862515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]